menaquinone-7/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
menaquinone-7 — decreases plasma desphospho-uncarboxylated matrix Gla protein (dp-ucMGP)
Evidence strength: very limited.Finding“Dp-ucMGP decreased significantly and dose-dependently in the 180 μg and 360 μg MK-7 supplementation groups (P time*treatment < 0.001) after 12 weeks, by 31% and 46% respectively, while dp-ucMGP levels remained unchanged after placebo treatment.”
Quoted verbatim from The effect of menaquinone-7 supplementation on circulating species of matrix Gla protein.. - Study
- RCT
- Duration
- 3 months
- Dose
- 180 μg/d or 360 μg/d MK-7 for 12 weeks
- Population
- Sixty healthy participants aged 40-65 y; 180 μg/d or 360 μg/d MK-7 versus placebo for 12 weeks
The effect of menaquinone-7 supplementation on circulating species of matrix Gla protein.2012PMID:2306276610.1016/j.atherosclerosis.2012.09.019Permalink
To cite this finding: https://catalystproject.ai/e/01M5JC7ZDM90KC976RPSE8DAR3